Industry-leading portfolio of water-free ophthalmic therapeutics
What is new about Novaliq’s products?
Novaliq develops first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first and only water-free technology, increasing residual time on the eye and enabling high bio-availability of active pharmaceutical ingredients (API) with excellent tolerability and safety with reduced extra-ocular systemic exposure. EyeSol® unlocks the full potential of APIs by generating novel drug products often with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.
ophthalmic solution of 0.1% cyclosporine A in EyeSol® developed to treat aqueous deficient DED
first drug developed to treat DED associated with Meibomian gland dysfunction in a highly effective way
First-in-class, preservation free eye treatment for tear film stabilization in dry eye.
(available in Europe, Australia and New Zealand)
First-in-class, preservative-free and clear eye drop containing 0.2% Omega-3 fatty esters.
What are the benefits of Novaliq’s products?
Clearly differentiated products based on our water-free EyeSol® platform. The key benefits are:
- Excellent suspendability and solubility of poorly soluble drugs
- Strong stability enhancement of antibodies, proteins and small molecules
- Optimal spreading and wetting abilities
- Strongly enhanced penetration
- Excellent safety and tolerability profile
- No preservatives
For which indications are products in development?
Dry Eye Disease (DED), Glaucoma and Retinal Diseases.
What products are next in the pipeline?
- CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II, for the treatment of moderate to severe DED.
- NovaTears®+Omega-3 – a first-in-class, preservative-free and clear eye drop containing 0,2% Omega-3. It stabilizes the lipid layer and reduces the evaporation of the underlying water phase of the tear film.
What clinical trials are currently under way?
- CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II for the treatment of moderate to severe DED (CYS-002).
- NovaTears® – a first-in-class, preservative free ophthalmic artificial tear for patients with mild to moderate dry eye disease (NT-004).
- NOV03 – a first-in-class, preservative free drug treatment addressing MGD and evaporative-caused DED (SEECASE-trial).
What are Novaliq’s products?
Novaliq offers an industry-leading portfolio of new, water-free and IP-protected ophthalmic therapeutics with proven market and clinical success.